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During food processing and storage, and in tissues and fluids under physiological conditions, the Maillard reaction occurs.
During this reaction, reactive 1,2-dicarbonyl compounds arise as intermediates that undergo further reactions to form
advanced glycation end products (AGEs). Diet is the primary source of exogenous AGEs. Endogenously formed AGEs
have been proposed as a risk factor in the pathogenesis of diet-related diseases such as diabetes, insulin resistance,
cardiovascular diseases, or chronic disease. AGEs may differently contribute to the diet-related exacerbation of oxidative
stress, inflammation, and protein modifications. Here, to understand the contribution of each compound, we tested
individually, for the first time, the effect of five 1,2-dicarbonyl compounds 3-deoxyglucosone (3-DG), 3-deoxygalactosone
(3-DGal), 3,4-dideoxyglucosone-3-ene (3,4-DGE), glyoxal (GO), and methylglyoxal (MGO) and four different glycated
amino acids N-ε-(carboxyethyl)lysine (CEL), N-ε-(carboxymethyl)lysine (CML), methylglyoxal-derived hydroimidazolone-1
(MG-H1), and pyrraline (Pyrr) in a cell line of human keratinocytes (HaCaT). We found that most of the glycated amino
acids, i.e., CEL, CML, and MG-H1, did not show any cytotoxicity. At the same time, 1,2-dicarbonyl compounds 3-DGal,
3,4-DGE, GO, and MGO increased the production of reactive oxygen species and induced cell death. MGO induced cell
death by apoptosis, whereas 3-DGal and 3,4-DGE induced nuclear translocation of the proinflammatory NF-κB
transcription pathway, and the activation of the pyroptosis-related NLRP3 inflammasome cascade. Overall, these results
demonstrate the higher toxic impact of 1,2-dicarbonyl compounds on mucosal epithelial cells when compared to glycated
amino acids and the selective activation of intracellular signaling pathways involved in the crosstalk mechanisms linking
oxidative stress to excessive inflammation.
1. Introduction
Advanced glycation end products (AGEs) are a heterogeneous
group of molecules formed during the Maillard reaction,
which is a spontaneous reaction initiated by a nucleophilic
addition between the free amino group of a protein, amino-
phospholipid, or nucleic acid and the carbonyl group of a sac-
charide [1, 2]. Protein glycation can occur in vivo in tissues
and fluids under physiological conditions. It is a slow and con-
tinuous process that drives AGE accumulation in tissues
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during ageing [3]. However, it also takes place ex vivo, during
food preparation such as baking, cooking, or frying and during
storage [4].
Diet is the main exogenous source of AGEs. It has also
been described that AGEs are endogenously produced after
a high sugar intake, substantially from fructose [5]. In fact,
this high fructose consumption generates an increase in
AGE levels in tissue and plasma [6, 7].
RAGE (receptor for AGEs) is a multiligand member of the
immunoglobulin superfamily of cell surface molecules that,
together with AGER1, AGER2, AGER3 receptors, mediates
the biological action of AGEs [8]. Nonetheless, some debate
persists over the physiological substrate(s) of RAGE and the
validity of several poorly characterized AGE-BSA preparations
to serve asmodels for protein-boundAGEs in the body [9, 10].
AGEs-RAGE interaction increases ROS formation [11–14],
which initiates several signal transduction cascades involving
kinases such as P44/P42 MAPK (ERK1/2), PI3K-AKT or
P38 MAPK, and NF-κB activation [15–18]. This leads to the
production of inflammatory molecules such as cytokines or
chemokines that eventually induce inflammation, apoptosis,
and proliferation [19–23]. Furthermore, it has been described
that AGEs can activate the NLRP3 inflammasome via oxida-
tive stress and inflammation [24, 25].
There is evidence of an existing relationship between
endogenous AGE production, AGEs-RAGE interaction, and
chronic hyperglycemia [3, 26, 27]. AGE-induced oxidative
stress contributes to the most common diabetes-associated
complications such as insulin resistance, atherosclerosis,
coronary artery disease, endothelial dysfunction [28], and
diabetic nephropathy or retinopathy [29–33].
Upon interaction with RAGE, it has been proposed that
AGEs increase oxidative stress. An increase in the intracellu-
lar levels of H2O2, O2
•–, and NO• has been found in endothe-
lial cells [34, 35], macrophages [36], and cardiomyocytes
[37]. The elevation of oxidative stress upon interaction with
RAGE affects mitochondrial function and cell metabolism
in various pathological conditions [38, 39].
One of the main challenges to be confronted is that AGEs
are a heterogeneous group of different molecules with differ-
ent chemical structures, and not all of them might exert the
same biological effects. Most of the published studies use gly-
cated albumin or a mixture of different AGEs to investigate
their biological activities. Since laboratories usually produce
these own compounds, the results are sometimes unreliable
and difficult to reproduce. In addition, a more detailed study
about the individual cytotoxicity of each compound might be
of interest.
To solve these drawbacks, we studied the cytotoxicity of
nine different compounds, specifically five 1,2-dicarbonyls:
3-deoxyglucosone (3-DG), 3-deoxygalactosone (3-DGal),
3,4-dideoxyglucosone-3-ene (3,4-DGE), glyoxal (GO), and
methylglyoxal (MGO); and four glycated amino acids:
N-ε-(carboxyethyl)lysine (CEL), N-ε-(carboxymethyl)lysine
(CML), methylglyoxal-derived hydroimidazolone-1 (MG-
H1), and pyrraline (Pyrr) (Figure 1), in a cell model of trans-
formed keratinocytes. The ability to increase oxidative stress,
to induce inflammatory pathways, and the type of cell death
was investigated.
2. Material and Methods
2.1. Glycated Amino Acids and 1,2-Dicarbonyls Synthesis.
Test substances for cell assays were synthesized as described
beforehand: the dicarbonyls 3-deoxyglucosone (3-DG) [40],
3-deoxygalactosone (3-DGal) [40], and 3,4-dideoxygluco-
sone-3-ene (3,4-DGE) [41] with Z-3,4-DGE being the pre-
dominant form and the glycation compounds pyrraline
(Pyrr) [42, 43], N-ε-(carboxymethyl)lysine (CML) [44],
N-ε-(carboxyethyl)lysine (CEL) [44], and methylglyoxal-
derived hydroimidazolone-1 (MG-H1) [44]. Methylglyoxal
(MGO) was obtained from Merck KGaA (Darmstadt, Ger-
many) and glyoxal (GO) from Fisher Sci (Madrid, Spain).
2.2. Cell Culture. HaCaT cells (CLS Cell Lines Service) were
grown in Dulbecco’s Modified Eagle’s medium (DMEM) cell
culture medium supplemented with 4.5 g/L glucose (Merck
KGaA, Darmstadt, Germany), 15mmol/L 4-(2-hydro-
xyethyl)-1-piperazineethanesulfonic acid (HEPES) (Merck
KGaA, Darmstadt, Germany), 2mmol/LL-glutamine (Merck
KGaA, Darmstadt, Germany), 10% FBS Merck KGaA (Darm-
stadt, Germany), and 1% antibiotic-antimycotic cocktail
(Gibco, Thermo Fisher Scientific, Waltham, MA, USA). Cells
were cultured at 37°C in a humidified 5% CO2 environment.
Cell culture medium was freshly changed every 2 days. Cells
were subcultured every 4 days. Briefly, cells were detached
using freshly prepared trypsin/EDTA solution (Merck KGaA,
Darmstadt, Germany) and incubated at 37°C for 10 minutes.
Cells were collected by centrifugation at 300 x g for 5 minutes.
Finally, cells were seeded at a split ratio of 1 : 10. To perform
the experiments, harvested and centrifuged cells were counted
using a Neubauer chamber and seeded in cell culture plates at
a density of 2:5 × 104 cells/mL. Cells were always allowed to
attach for 48 hours before starting the experiment. Cells were
routinely tested for mycoplasma contamination.
2.3. Cell Viability Assay by MTT Reduction. To perform the
assay, cells were seeded in 96-well plates in 100μL complete
DMEM with 4.5 g/L glucose. After 48 hours, cells were incu-
bated with the different compounds to be tested. After 48
hours incubation, 10μL 5mg/mL MTT (Merck KGaA,
Darmstadt, Germany) were added to each well and cells were
incubated at 37°C and 5% CO2 for 4 hours. Then, 100μL lysis
buffer (20% SDS and 50% dimethylformamide, pH4.7) was
added to each well, and cells were left in the incubator at
37°C and 5% CO2 overnight [45]. Absorbance was measured
at 570 nm vs. 690nm in a Varian Cary 50-MPR UV-Vis spec-
trophotometer (Agilent Technologies, Santa Clara, CA,
USA). Results are shown as the mean of six samples ± SEM.
2.4. Cell Viability Assay by Trypan Blue Exclusion. The cell
death inhibitors were previously dissolved in 100% dimethyl
sulfoxide (DMSO) and then added to culture media from a
1000x stock solution. Therefore, DMSO concentration was
never higher than 0.1%, and this concentration was also
added to the control group. 2μmol/L Ferrostatin-1 (0,001%
DMSO) (Cayman Chemical, Ann Arbor, MI, USA), 2mM
3-methyladenine (0,1% DMSO) (Cayman Chemical, Ann
Arbor, MI, USA), 100μmol/L Necrostatin-1 (0,001%)
(Cayman Chemical, Ann Arbor, MI, USA), or 10μM
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Quinoline-Val-Asp-Difluorophenoxymethyl Ketone (Q-VD-
OPh) (0,001% DMSO) (Merck KGaA, Darmstadt, Germany)
were employed as inhibitors of ferroptosis, autophagy, necrop-
tosis, and apoptosis, respectively.
To discover the involvement of oxidative stress,
10mmol/LN-acetyl-cysteine (NAC) (Merck KGaA, Darm-
stadt, Germany) was used. This compound was freshly dis-
solved in a culture medium at pH7.4 and added to the
culture media from a 100mmol/L stock solution. The culture
medium was adjusted to the same volume in each group.
To perform the assay, cells were seeded in 24-well plates
containing 500μL complete DMEM with 4.5 g/L glucose.
After 48 hours, cells were firstly incubated with the corre-
sponding cell death inhibitor or with NAC for 30 minutes
in the incubator at 37°C and 5% CO2. Then, the different
1,2-dicarbonyls were added to the culture media. After
48 hours of incubation, cells were detached using trypsi-
n/EDTA solution. Detached and attached cells were collected
into the same tube. Cells were stained with 0.4% trypan blue
(Merck KGaA, Darmstadt, Germany) using a dilution 1 : 1,
allowing the mixture to incubate for 3 minutes at RT. Cells
were counted using a Neubauer chamber, and the ratio
between viable and nonviable cells was calculated. Results
are shown as the mean of three samples ± SEM.
2.5. Cell Cycle Analysis. For cell cycle analysis, cells were
seeded in 24-well plates in 500μL complete DMEM with
4.5 g/L glucose. After 48 hours, cells were incubated with
the different compounds to be tested. After 48 hours of incu-
bation, cells were detached using trypsin/EDTA solution.
Detached and attached cells were added and collected into
the same tube. Cells were centrifuged at 300 x g for 5 minutes.
Cell pellet was washed twice in PBS and centrifuged at 300 x g
for 5 minutes. Cells were then fixed in cold 70% ethanol and
left at 4°C for at least 30 minutes. After that, cells were
washed once in 2mL PBS supplemented with 2% bovine
serum albumin (BSA) and centrifuged at 300 x g for 5
minutes. Then, the cell pellet was resuspended in 500μL
propidium iodide (PI)/ribonuclease (RNase) Solution (Immu-
nostep S.L, Salamanca, Spain), mixed well, and incubated for
15minutes at RT. Finally, cells were analyzed in a BDAccuri™
C6 flow cytometer (BD Biosciences, San Jose, CA, USA), and
data analysis was performed by using BD Accuri™ C6 Soft-
ware. At least 104 events per sample were analyzed. Results
are shown as the mean of three samples ± SEM.
2.6. Quantification of Intracellular and Mitochondrial ROS
Levels. To detect intracellular and mitochondrial ROS pro-
duction, cells were seeded, treated, and collected as described
above. To measure O2
•- production, cells were incubated in
500μL 5μmol/L dihydroethidium (DHE) (Bioquochem
S.L., Llanera, Spain) for 30 minutes at RT. H2O2 and
HNO3
- production was examined by incubating cells in
500μL 5μmol/L dihydrorhodamine 123 (DHR-123) (Bio-
quochem S.L, Llanera, Spain) for 30 minutes at RT. To mea-
sure mitochondrial O2
•- production, cells were incubated
with 500μL 5μmol/L MitoSOX™ Red (Invitrogen, Thermo
Fisher Scientific, Waltham, MS, USA) for 10 minutes at
37°C. Finally, cells were analyzed using a BD Accuri™ C6
flow cytometer (BD Biosciences, San Jose, CA, USA), and
data analysis was performed using BD Accuri™ C6 Software.
At least 104 events per sample were analyzed. Results are
shown as the mean of three samples ± SEM.
2.7. Annexin-V and 7-AAD Apoptosis Assay. To perform the
apoptosis assay, cells were seeded, treated, and collected as
described above. Cells were stained using the fluorescein iso-
thiocyanate (FITC) Annexin V Apoptosis Detection Kit with
7-aminoactinomycin D (7-AAD) (Immunostep S.L., Sala-
manca, Spain) and following the manufacturer’s instructions.
Briefly, cells were resuspended in 100μL Annexin V binding

























CML CEL Pyrr MG-H1
3-DG




Figure 1: Chemical structures of the compounds tested in the present study. CML: N-ε-carboxymethyllysine; CEL: N-ε-carboxyethyllysine;
Pyrr: pyrraline; MG-H1: methylglyoxal-derived hydroimidazolone 1; GO: glyoxal; MGO: methylglyoxal; 3-DG: 3-deoxyglucosone; 3,4-DGE:
3,4-dideoxyglucosone-3-ene; 3-DGal: 3-deoxygalactosone.
3Oxidative Medicine and Cellular Longevity
added, and cells were incubated for 15 minutes at RT in the
dark. After that, 400μL Annexin V binding buffer was added
to all samples. Finally, cells were analyzed using a BD
Accuri™ C6 flow cytometer (BD Biosciences, San Jose, CA,
USA), and data analysis was performed using BD Accuri™
C6 Software. At least 104 events per sample were analyzed.
To calculate the percentage of apoptotic cells, Annexin
V-FITC positive cells as well as Annexin V-FITC- and
7-AAD-positive cells were considered. Results are shown
as the mean of three samples ± SEM.
2.8. Protein Extraction. For protein extraction, cells were
seeded in 100mm plates containing 10mL of complete
DMEM with 4.5 g/L glucose. After 48 hours, cells were incu-
bated with the different compounds to be tested. After 48
hours of incubation, cells were detached using trypsin/EDTA
solution. Detached and attached cells were collected into the
same tube. Cells were centrifuged at 300 x g for 5 minutes.
Cell pellet was washed twice in PBS and centrifuged at 300
x g for 5 minutes. Then, cells were lysed in radioimmunopre-
cipitation assay (RIPA) lysis buffer (50mmol/L Tris-HCl,
pH7.4, 150mmol/L NaCl, 0.1% sodium dodecyl sulfate
(SDS), 1% Igepal C and 0.5% sodium deoxycholate) supple-
mented with freshly added 2μg/mL aprotinin, 1mmol/L
dithiothreitol (DTT), 10μg/mL leupeptin, 1μg/mL pepstatin,
1mmol/L phenylmethylsulfonylfluoride (PMSF), 1mmol/L
sodium fluoride, and 200μmol/L sodium orthovanadate for
30 minutes in ice. After incubation, cells were centrifuged
at 15,000 x g for 15 minutes at 4°C, and the supernatant con-
taining the proteins was transferred to a new tube. Proteins
were stored at -80°C.
Protein concentration was estimated using the colorimet-
ric Bradford assay [46] (Bioquochem S.L., Llanera, Spain).
The absorbance was measured at 595 nm in a Varian Cary
50-MPR UV-Vis spectrophotometer (Agilent, Santa Clara,
CA, USA).
2.9. Western Blot. To perform western blot assay, 30-50μg of
proteins were mixed 1 : 4 with loading buffer (250mmol/L
Tris-HCl, 40% glycerol, 8% SDS, 0.2% bromophenol blue,
and 2.8% β-mercaptoethanol). Then, proteins larger than
50 kD were separated in a 10%, and proteins smaller than
50 kD were separated 15% SDS-polyacrylamide gel electro-
phoresis (PAGE) using a Mini-PROTEAN® Tetra Vertical
Electrophoresis Cell (Bio-Rad, Hercules, CA, USA). Then,
proteins were electrotransferred to Immobilon®-P polyviny-
lidene difluoride (PVDF) membranes (Millipore, Merck
KGaA, Darmstadt, Germany) using a Mini Trans-Blot® Cell
(Bio-Rad, Hercules, CA, USA). After that, the membranes
were always stained with Ponceau solution (Bioquochem
S.L, Llanera, Spain) to confirm that the proteins were cor-
rectly transferred. Then, membranes were incubated with
5% nonfat dry milk in TBS-Tween buffer (TBS-T, Tris-HCl
20mmol/L, pH7.4, 150mmol/L NaCl, 0.05% Tween) for 1
hour at RT. After that, membranes were incubated overnight
at 4°C with the corresponding primary antibody anti-α-tubu-
lin (1 : 2000, #ab7291, abcam, Cambridge, UK), anti-β-actin
(1 : 8000, #sc-69879, Santa Cruz Biotechnology, Santa Cruz,
CA, USA), anti-catalase (1 : 5000, #219010, Calbiochem,
Merck KGaA, Darmstadt, Germany), anti-gasdermin D
(1 : 1000, #93709, Cell signaling, Danvers, MS, USA), anti-IκBα
(1 : 1000, #4814 Cell signaling, Danvers, MS, USA), anti-phos-
pho-IκBα (Ser32/36) (1 : 1000, #9246 Cell signaling, Danvers,
MS, USA), anti-IKKβ (1 : 1000, #2370, Cell signaling, Danvers,
MS, USA), anti-phospho-IKKα/β (Ser176/180) (1 : 1000,
#2697, Cell signaling, Danvers, MS, USA), anti-NF-κB p65
(1 : 1000, #8242, Cell signaling, Danvers, MS, USA), anti-
NLRP3 (1 : 1000, #AG-20B-0014, AdipoGen, Liestal, Switzer-
land), anti-SOD1 (1 : 5000, #574597, Calbiochem, Merck
KGaA, Darmstadt, Germany), and anti-SOD2 (1 : 5000 #06-
984, Millipore, Merck, KGaA, Darmstadt, Germany). Primary
antibodies were visualized by binding horseradish peroxidase-
(HRP-) conjugated anti-rabbit (#12-348, Sigma-Aldrich,
Merck KGaA, Darmstadt, Germany), anti-mouse (#12-349,
Sigma-Aldrich, Merck KGaA, Darmstadt, Germany), or anti-
sheep (#12-342, Sigma-Aldrich,Merck KGaA, Darmstadt, Ger-
many) immunoglobulin G (IgG) secondary antibodies for 1
hour at RT. Antibodies were further detected with Immobilon®
Western Chemiluminescent HRP Substrate (Millipore, Merck
KGaA, Darmstadt, Germany). Then, an Amersham Hyper-
film™ photographic film (Fisher Scientific, Thermo Fisher
Scientific, Waltham, MS, USA) was exposed to the membrane
and further developed and fixed in a dark room. Blots were
all scanned at 300 dots per inch (dpi) grayscale, and densi-
tometry was quantified by the open-source FIJI software.
Results are shown as the mean of 3 samples ± standard error
of themean ðSEMÞ.
2.10. Statistical Analysis. Unless otherwise indicated, data
are presented as mean ± standard error of themean ðSEMÞ.
Under normal distribution, differences were estimated
using student’s t-test. When samples did not follow a normal
distribution, a nonparametric Mann–WhitneyU Test was per-
formed. Results were only considered statistically significant if
p < 0:05. Graphs and statistical analysis were done using the
Prism 8 software (GraphPad Software, Inc, USA).
3. Results
3.1. Most 1,2-Dicarbonyls Were Cytotoxic, whereas Glycated
Amino Acids Did Not Alter Cell Viability. As mentioned
above, most of the studies published in which the cytotoxicity
of AGEs was tested have used albumin glycated by diverse
techniques or a solution containing a mixture of different
AGEs at unknown concentrations. This, in addition to the
many different protocols, makes reproducibility a challeng-
ing task. Moreover, to find a relation between the structure
and function of these compounds is one of the main aims
of this work.
Hence, several synthesized glycated amino acids (CEL,
CML, MG-H1, and Pyrr) and 1,2-dicarbonyls (3-DG,
3-DGal, 3,4-DGE, GO, and MGO) were tested on the kerati-
nocyte cell line HaCaT using a wide concentration range to
assay their possible cytotoxicity in cell culture. After attach-
ment, cells were incubated for 48 hours with these com-
pounds, and an MTT viability assay was performed.
Only 1,2-dicarbonyls showed cytotoxicity in cell culture
(Figure 2(a)). They displayed a clear dose-response, being
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3-DGal, GO and MGO significantly cytotoxic compared to
the control group above a concentration of 500μmol/L.
When cells were incubated with 3-DGal, the viability of the
cells was significantly reduced by 82% at 750μmol/L. In the
case of GO, cell viability was decreased by 59% when tested
at a concentration of 1mmol/L. No surviving cells were
found when cultured with 750μmol/L MGO, and a cytotox-
icity of almost 50% with a concentration of 500μmol/L was
observed. The chemically the most reactive dicarbonyl 3,4-
DGE was found to be also the most cytotoxic compound.
Concentrations of the compound above 50μmol/L were
already significantly cytotoxic, and cell viability after the
treatment of the cells with 75μmol/L 3,4-DGE was dramati-
cally reduced until viability of 11% (Figure 2(b)).
On the other hand, glycated amino acids were much less
cytotoxic than 1,2-dicarbonyls, since only Pyrr, at a concentra-
tion higher than 500μmol/L, was able to reduce the viability of
HaCaT cells in culture. Thus, 1mmol/L Pyrr decreased MTT
reduction to 61.58%. Although, the cells did not show any
signs of cell damage when observed under the microscope.
This indicates that Pyrr could affect both proliferation and
mitochondrial activity instead of increasing cytotoxicity of
HaCaT cells since MTT assay cannot discriminate between
them. Interestingly, incubation with CEL, CML, MG-H1,
and 3-DG did not show any sign of cell damage
(Figure 2(c)). Thus, the following assays addressing individual
mechanisms of cytotoxicity were performed only with the
dicarbonyl compounds.
3.2. GO and MGO Retarded the Cell Cycle in HaCaT Cells.
The progression of cell cycle upon incubation with these
compounds was assayed to study whether these compounds
might reduce cell proliferation and then alter the cell cycle.
Thus, cells were incubated with 3-DGal, 3,4-DGE, GO, and
MGO for 48 hours, and after that, the cell cycle was studied,
staining the cells with PI and, then, analyzing them by flow
cytometry. It was found that 3-DGal did not show any
change in cell cycle progression compared to control cells.
However, 3,4-DGE significantly decreased the number of
cells in G0/G1 phase when compared to the control group.
On the other hand, GO and MGO significantly increased




















































































Figure 2: Effect of individual 1,2-dicarbonyls and glycated amino acids on cell viability. (a) Cell viability upon incubation with
individual 1,2-dicarbonyls. (b) Cell viability upon incubation with 3,4-DGE. (c) Cell viability upon incubation with individual glycated
amino acids. Results are expressed as mean ± SEM (n = 6). ∗p < 0:05 vs. CON, ∗∗p < 0:01 vs. CON, ∗∗∗p < 0:001 vs. CON.
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arrest in the S phase due to activation of the S-phase DNA
damage checkpoint (Figure 3).
3.3. Antioxidant NAC Recovered 1,2-Dicarbonyl-Mediated
Cell Death. It has been proposed that AGEs and their precur-
sors might increase oxidative stress, but this fact was not
previously demonstrated with isolated 1,2-dicarbonyl com-
pounds. Consequently, to elucidate whether they were
increasing ROS production in this cell culture model and
whether cytotoxicity might depend on free radicals, the effect
of the antioxidant NAC in preventing cell death induced by
these compounds was studied. Thus, cells were preincubated
for 30 minutes with 10mmol/L NAC, and then, the 1,2-dicar-
bonyls 3-DGal, 3,4-DGE, GO, and MGO were added to the
cell culture without removing NAC. After 48 hours of incuba-
tion, cell viability was assayed by trypan blue exclusion.
It was found that preincubation with NAC prevented the
cytotoxicity of 1,2-dicarbonyls. Upon incubation with 3-
DGal and 3,4-DGE, cells showed blebs and irregular borders,
an indication for cell damage, which was highly prevented
upon coincubation with NAC. Importantly, in the case of
MGO incubation, a lot of the cells showed blebs, and cell
integrity was completely lost in most cases. Although, when
coincubating the cells with NAC, the cell morphology was
equal to that observed in the control cells (Figure 4(a)). The
role of NAC to prevent the cytotoxicity of 1,2-dicarbonyls
was studied by trypan blue exclusion since NAC interferes
with formazan, and it cannot be employed in MTT assay.
Thus, we found that NAC prevented the cytotoxicity of
1mmol/L 3-DGal (Figure 4(b)). Similarly, NAC completely
prevented the cytotoxicity and recovered cell viability from
84% to 96.97% when cells were treated with 100μmol/L
3,4-DGE (Figure 4(c)). Interestingly, a reduction of cell via-
bility by GO was not found when trypan blue exclusion was
employed, suggesting an effect of the compound on the mito-
chondrial metabolism of the cells (Figure 4(d)). Finally, the
most remarkable result was obtained within the MGO group.
Thus, 750μmol/L MGO treatment reduced the viability of
HaCaT cells to an 18.33%. NAC preincubation recovered
the viability almost completely to 94% (Figure 4(e)).
Altogether, these data account for a feasible role of ROS in
mediating 1,2-dicarbonyls cytotoxicity.
3.4. 1,2-Dicarbonyls Caused an Increase in ROS and the
Production of Antioxidant Enzymes. Then, it was further stud-
ied whether 1,2-dicarbonyls triggered ROS production in the
human keratinocytes HaCaT cells. Therefore, cells were treated
with 3-DGal, 3,4-DGE, GO, and MGO for 48 hours and
stained with DHR-123, DHE, and MitoSOX™ Red, and finally
analyzed by flow cytometry. Interestingly, individual 1,2-dicar-
bonyls increased the production of the species measured in
HaCaT cells, among the different 1,2-dicarbonyls, GO, and
MGO caused a higher ROS production than 3-DGal and 3,4-
DGE. Furthermore, superoxide was increased more than twice
by MGO than the control group (Figures 5(a)–5(c)).
Because of increasing free radicals’ production, cells
naturally increase the production of antioxidant enzymes.
To evaluate the effect of 1,2-dicarbonyls on the production
of antioxidant enzymes as a consequence of the increment
of the free radicals produced, cells were incubated with the
1,2-dicarbonyls 3-DGal, GO, and MGO for 48 hours, and
the levels of SOD1, SOD2, and catalase were studied by
western-blot. In the case of SOD1, only GO significantly
increased its levels. However, 3-DGal and GO increased
SOD2. The production of CAT did not change after
treatment. Besides, since the production of peroxides was
increased in the cells upon incubation with 1,2-dicarbonyls,
the ratio between catalase and SOD2 production was also
studied. Although there was a relative increase in the SOD2/-
CAT ratio when cells were incubated with 1,2-dicarbonyls,
especially GO andMGO, the differences were not statistically
significant between groups (Figures 5(d)–5(h)).
3.5. MGO Induced Cell Death by Apoptosis in HaCaT Cells. It
remains to be determined how 1,2-dicarbonyls lead to cell
death and if individual 1,2-dicarbonyls cause cell death by
the same mechanism. Therefore, it was firstly assayed
whether cells might be dying by apoptosis. To investigate
that, cells were incubated with the 1,2-dicarbonyls 3-DG, 3-
DGal, 3,4-DGE, GO, and MGO for 48 hours, and after that,
they were stained with Annexin-V and 7-AAD and analyzed
by flow cytometry.
It was found that the number of apoptotic cells did not
change between the control group and cells incubated with
3-DG, 3-DGal, 3,4-DGE, and GO. Outstandingly, the num-
ber of cells dying by apoptosis upon MGO incubation was
greatly increased, and it reached a mean of 85.35% of the total
cells (Figures 6(a) and 6(b)).
To confirm that cells were dying by caspase-mediated
apoptosis when incubated with MGO, cells were preincu-
bated with the inhibitor of caspase Q-VD-OPh for 30
minutes, and after that, MGO was added to the cell culture.
Cells were incubated with both compounds for 48 hours,
and then, cell viability was assayed by trypan blue exclusion.
When incubating the cells with MGO, they showed blebs and
cell integrity was completely lost in most cases. Although,
when coincubating the cells with this 1,2-dicarbonyl and
the inhibitor of caspases, cell morphology was greatly recov-
ered, the number of cells displaying the morphology
observed in the control cells was increased (Figure 6(d)). It
was found that cell viability was significantly recovered upon
preincubation with q-VD-OPH and it consequently pointed
to apoptosis as the most feasible cell death mechanism pro-
duced by MGO (Figure 6(c)).
After that, we used a series of other cell death inhibitors
to decipher the cell death mechanism by which cells were
dying when incubated with 3-DGal and 3,4-DGE. Hence,
we preincubated cells with Ferrostatin-1, an inhibitor of
ferroptosis; with 3-MA, an inhibitor of autophagy; and
Necrostatin-1, an inhibitor of necroptosis, for 30 minutes,
and after that, 3-DGal and 3,4-DGE were added to the cell
culture. Cells were incubated with both compounds for 48
hours, and then, cell viability was assayed by trypan blue
exclusion. When cells were incubated with 3-DGal and 3,4-
DGE, some cells showed irregular borders and blebs. Never-
theless, when cells were coincubated with 1,2-dicarbonyls
and cell death inhibitors, no recovery of the cell morphology
was noticed (Figure 7(a)). Similarly, when cells were
6 Oxidative Medicine and Cellular Longevity
incubated with the 1,2-dicarbonyls and inhibitors of ferrop-
tosis, autophagy, and necroptosis, cell viability was not recov-
ered in any of the assayed conditions (Figure 7(b)).
3.6. 3-DGal and 3,4-DGE Activated the Inflammatory
Pathways of NF-κB and NLRP3 Inflammasome. Given the
impact on cell viability derived from the exposure of the
1,2-dicarbonyl compounds 3,4-DGE, 3-DGal, and 3-DG,
and the AGE Pyrr, the subsequent analyses were structured
to understand which pathways were underlying the cytotox-
icity involved in this reduction of cell viability. The
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Figure 3: Effect of individual 1,2-dicarbonyls on cell cycle. (a) Propidium iodide fluorescence was measured by flow cytometry. One
representative experiment is shown. (b) Cell population percentage in each stage of cell cycle. Here, cell treatments consisted of
750μM 3-DGal, 75μM 3,4-DGE, 1mM GO, and 500μM MGO. Results are expressed as mean ± SEM (n = 3). ∗∗p < 0:01 vs. CON,
∗∗∗p < 0:001 vs. CON.
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Figure 4: Cell viability recovery after coincubation with 1,2-dicarbonyls and NAC. (a) A representative micrograph for each condition is
shown. For each condition, micrographs shown in the first row were taken at 100x original magnification, and micrographs in the second
row were taken at 400x original magnification. Arrows indicate blebs. (b) Cell viability upon coincubation with 3-DGal and NAC. (c) Cell
viability upon coincubation with 3,4-DGE and NAC. (d) Cell viability upon coincubation with GO and NAC. (e) Cell viability upon
coincubation with MGO and NAC. Results are expressed as mean ± SEM (n = 3). ∗p < 0:05 vs. CON, ∗∗p < 0:01 vs. CON, ∗∗∗p < 0:001 vs.
CON, ##p < 0:01 vs. no 1,2-dicarbonyl, ###p < 0:001 vs. no 1,2-dicarbonyl.
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evaluated, respectively, on the amino acid residues
Ser176/180 and Ser32/36. IKK phosphorylation values are
shown as the ratio between the phosphorylated protein and
the total protein in the whole protein extract of the samples
examined. IKK phosphorylation levels were significantly
increased in the 3,4-DGE and 3-DGal treatment groups com-
pared to the control group. Furthermore, these values are
comparable to each other. On the other hand, there is no evi-
dence of IKK phosphorylation significantly different from
the control group for the samples treated with 3-DG. The
consequent phosphorylation of the IκBα protein was then
evaluated. It can be seen that the observed trend for IKK
phosphorylation was comparable to that of IκBα phosphory-
lation. In particular, as regards the parameters related to the
phosphorylation both of IKK and of IκBα, the phosphoryla-
tion appears to be tripled for 3-DGal and slightly more than
tripled for 3,4-DGE compared to the control. By analyzing
the data related to the 3-DG and Pyrr groups, these are com-
parable to the control for both parameters. To evaluate the
translocation of NF-κB at the nuclear level, the presence of
this factor in the cytosolic protein extract and the nuclear
protein extract was tested. The results are expressed as the
ratio between cytosolic NF-κB and nuclear NF-κB. The
results show a significant nuclear translocation of NF-κB in
HaCaT cells treated with 3,4-DGE. Nuclear NF-κB is more
than five times higher compared to the control. Furthermore,
regarding the 3-DGal group, the translocation of NF-κB at
the nuclear level can be highlighted. Despite the high
standard deviation, it can be seen that the presence of the
transcription factor in the nucleus is approximately four
times the same in the control group (Figure 8).
Similar results were obtained when the effects on the
modulation of the NLRP3 inflammasome pathway were
evaluated. As shown in Figure 9, the expression of NLRP3
is more than doubled in the 3,4-DGE and 3-DGal treatment
groups compared to the control group. Exactly as observed
for the other markers previously examined, the two groups
are comparable to each other. However, it should be consid-
ered that the exposure concentration of keratinocytes to 3,4-
DGE was 10 times lower than that of the exposure to 3-DGal.
Following the evaluation of the expression of NLRP3 in the
groups under analysis, it was decided to evaluate its activa-
tion by searching for the cleaved form of gasdermin-D
(GSDMD). NLRP3, once activated, can activate caspase-1
that can cleave (in addition to, for example, the most studied
interleukin-1β) the GSDMD. The N-terminal residue of
GSDMD (at 30 kDa) is then able to form transmembrane
pores. Figure 10 also shows the analysis of the inactive form
of GSDMD (Pro-GSDMD) and the active form (Activated
GSDMD) production in keratinocytes treated with 3-DGal,
3,4-DGE, Pyrr, and 3-DG. The groups exposed to 3,4-DGE
and 3-DGal, in addition to causing an increase in the expres-
sion of NLRP3 (as seen above), also showed the activation of
GSDMD; in these groups of treatment, GSDMD was about
five times higher than the inactive form. In contrast, the
3-DG and Pyrr groups did not show any difference in the
presence of the two forms compared to the control group.
4. Discussion
In the present manuscript, we report for the first time the
biological effects that individual glycated amino acids and
1,2-dicarbonyls induce in a keratinocyte cell model. We
found that most of the assayed 1,2-dicarbonyls are cytotoxic
at a concentration ranging from 50μmol/L to 500μmol/L,
whereas glycated amino acids do not alter cell viability.
Hence, 3-DGal, 3,4-DGE, GO, and MGO highly reduce cell































































Figure 5: Free radical and antioxidant enzymes production upon application of 1,2-dicarbonyls. (a) Production of peroxide and peroxynitrite
as measured by DHR fluorescence intensity. (b) Production of superoxide as measured by DHE fluorescence intensity. (c) Production of
mitochondrial superoxide as measures by MitoSOX fluorescence intensity. (d) Representative western blot experiment. (e) Production of
SOD1 as analyzed by quantification of western blot optical density. (f) Production of SOD2 as analyzed by quantification of western blot
optical density. (g) Production of catalase as analyzed by quantification of western blot optical density. (h) Ratio between the production
of SOD2 and catalase. Arbitrary 1.0 value was given to the WT group. Here, cell treatments consisted of 750μM 3-DGal, 75μM 3,4-DGE,
1mM GO, and 500μM MGO. Results are expressed as mean ± SEM (n = 3). ∗p < 0:05 vs. CON, ∗∗p < 0:01 vs. CON, ∗∗∗p < 0:001 vs. CON.









































































































































































B03 CON 3 C03 3-DG 1 mM
D03 GO 1 mM D05 MGO 500 uM
C06 3-DGal 750 uM









































































Figure 6: Cell death by apoptosis after incubation with 1,2-dicarbonyls. (a) Annexin-V and 7-AAD fluorescence was measured by flow
cytometry. One representative experiment is shown. (b) Percentage of apoptotic cells in the cell culture. Positive cells for Annexin V and
for both Annexin V and 7-AAD were considered apoptotic. (c) Cell viability upon coincubation with MGO and the apoptosis
inhibitor Q-VD-OPh. (d) Cell viability recovers after coincubation with apoptosis inhibitor Q-VD-OPh. A representative micrograph for
each condition is shown. For each condition, micrographs shown in the first row were taken at 100x original magnification, and
micrographs in the second row were taken at 400x original magnification. Arrows indicate blebs. Here, cell treatments consisted of 1mM
3-DG, 750μM 3-DGal, 75μM 3,4-DGE, 1mM GO, and 500μM MGO. Results are expressed as mean ± SEM (n = 3). ∗∗∗p < 0:001 vs.
CON, ###p < 0:001 vs. no 1,2-dicarbonyl.
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that this antioxidant prevents the decrease in cell viability
caused by 1,2-dicarbonyls, which accounts for a possible role
of ROS in mediating 1,2-dicarbonyls cytotoxicity. Indeed, we
found that 1,2-dicarbonyls increase peroxide, peroxynitrite,
and superoxide production in cells, and therefore, the
production of SOD1 and SOD2 counters an excessive ROS
production. Finally, we found that the 1,2-dicarbonyl MGO
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Figure 7: Cell viability recovery after coincubation with cell death inhibitors. (a) A representative micrograph for each condition is shown.
For each condition, micrographs shown in the first row were taken at 100x original magnification, and micrographs in the second row were
taken at 400x original magnification. Arrows indicate blebs. (b) Cell viability upon coincubation with the ferroptosis inhibitor Ferrostatin-1.
(c) Cell viability upon coincubation with the autophagy inhibitor 3-MA. (d) Cell viability upon coincubation with the necroptosis inhibitor
Necrostatin-1. Here, cell treatments consisted of 750μM3-DGal and 75μM3,4-DGE. Results are expressed asmean ± SEM (n = 3). #p < 0:05
vs. no 1,2-dicarbonyl, ##p < 0:01 vs. no 1,2-dicarbonyl.
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3-DGal and 3,4-DGE activate the NF-κB pathway and drive
the activation of NLRP-3 inflammasome, which triggers cell
death by pyroptosis.
Up to now, most of the studies that have been published
in the field of the biological and pathological roles of AGEs
have been conducted using glycated albumin or a mixture









































































































































Figure 8: Activation of the NF-κB pathway upon incubation with 1,2-dicarbonyls. (a) IKKαβ phosphorylation. A representative western-blot
experiment is shown. Graphic represents the ratio between the production of p-IKKαβ and total IKKαβ as analyzed by quantification of
western blot optical density. (b) IκB phosphorylation. A representative western blot experiment is shown. Graphic represents the ratio
between the production of IκB and total IκB as analyzed by quantification of western blot optical density. (c) NF-κB activation. A
representative western blot experiment is shown. Graphic represents the ratio between the production of nuclear p65 NF-κB and cytosolic
NF-κB as analyzed by quantification of western blot optical density. Arbitrary 1.0 value was given to the CON group. Here, cell treatments
consisted of 750μM 3-DGal, 75μM 3,4-DGE, 1mM Pyrr, and 1mM 3-DG. Results are expressed as mean ± SEM (n = 3). ∗p < 0:05 vs.
CON, ∗∗p < 0:01 vs. CON, ∗∗∗p < 0:001 vs. CON.
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of different AGEs to perform the experiments. The proce-
dures used to obtain these substances widely vary from labo-
ratory to laboratory, usually following nonreproducible
methodologies, making the results obtained between differ-
ent research groups hardly comparable. Moreover, AGEs
comprise an extensive variety of compounds, with each com-
pound being structurally very different from the other, and
thus, they might not exert the same effects in cellular and ani-
mal models. In addition to AGEs, albumin glycation produces
1,2 dicarbonyls. Therefore, there is a lack of reproducible
methodology, and it is necessary that the role of individual
AGEs and 1,2-dicarbonyls should be investigated.
To perform our experiments, the most prevalent glycated
amino acids and 1,2-dicarbonyls in foods were synthesized to
assay the effects that they might produce individually in cell
culture. Since diet is a source of exogenous products of glyca-
tion, and the mouth is the first tissue in contact with these
compounds, we used an oral mucosa in vitro cell model,
using the human keratinocyte cell line HaCaT.We found dif-
ferent cytotoxic effects depending on the compound tested.
On the one hand, some of the best characterized glycated
amino acids, such as CEL and CML, were not cytotoxic in
our cell model. As it has been reported, these compounds
are present in the plasma of diabetic patients in a concentra-
tion up to 1.2μmol/L for CEL and 2.9μmol/L for CML and at
a concentration up to 1.7μmol/L and 4.9μmol/L, respec-
tively, in the plasma in type I diabetes and impaired renal
function patients [47]. It has been also reported that plasma
CEL/CML concentrations in chronic kidney disease patients
are 336nmol/L and 111 nmol/L, respectively [48]. Moreover,
in one study using endothelial progenitor cells, CEL and
CML up to a concentration of 4.58μmol/L and 4.90μmol/L,
respectively, showed no cell toxicity [49]. These concentra-
tions are much lower than our maximum concentration
tested, i.e., 1mol/L, which does not exert any cytotoxic effect
triggered by these two glycated amino acids. In the case of
MG-H1, its concentration according to several studies in
serum of nondiabetic patients is at 76:67 ± 35:93 nmol/L
[50] and in plasma at 109:97 ± 46:00 nmol/L [51]. Moreover,
the daily intake of CEL was calculated to be ~0.01mmol, of
CML~0.015mmol, and MG-H1~0.1mmol. In the case of
Pyrr, the intake was estimated to be around 0.08-0.16mmol
[52]. Again, these quantities are below the maximum ones
employed in this study, which do not show any harmful effect
on our cell model.
Furthermore, we have not found any cytotoxicity of
3-DG in our cellular model, which agrees with another study
where this 1,2-dicarbonyl compound was tested in PC12 cells
and no cytotoxicity was found [53]. It has been described that
the plasma concentration in type 2 diabetes patients of 3-DG
is 1.37μmol/L, of GO 0.74μmol/L, and of MGO 0.31μmol/L
[54]. In serum of patients with chronic kidney disease, the
amounts have been found to be of 1.64μmol/L for 3-DG,
1.72μmol/L for GO, and 1.08μmol/L for MGO [55]. In peri-
toneal dialysis fluids, 3-DGal has been detected at a concen-
tration of ≤16μmol/L and 3-DG at a concentration of
≤7μmol/L [56]. These numbers are below the concentration
of these compounds from which we see effects in keratino-
cytes. However, the concentration of 3,4-DGE in peritoneal
dialysis fluids is 9-22μmol/L [57], which is an amount that
already decreases cell viability in our cellular model.
Moreover, some studies using other cell types describe a
reduction in cell viability of ~22% with a concentration of
1mmol/L MGO in leukocytes [58] and 1.6mmol/L in
endothelial cells [59]. MGO is found at high concentrations
in Manuka honey [60]. Its cytotoxicity and its mediated
NF-κB activation have been reported by several groups
[61–63]. Besides, MGO has also been found to increase the
phosphorylation of the MAPK family members p-JNK,
p-ERK, and p-p38 and highly decrease the levels of MMP-9
and Bcl-2 [64]. MGO has also been associated with metabo-
lism and mitochondrial function, inhibiting glycolysis and
mitochondrial complex I [65, 66].
We found that the antioxidant NAC, a synthetic precur-
sor of the intracellular antioxidant glutathione (GSH), can
recover cell viability in a different degree upon treatment
with 3-DGal, 3,4-DGE, GO, and MGO. This is in accordance
with previous studies, which have shown that pretreatment
with NAC improved cell viability in MGO-treated cells
[67]. Furthermore, in another study, performed this time in
the pancreatic beta-cell line INS-1, it was reported that cell
viability decreased to 70% when cells were treated for 24
hours with 2mmol/L MGO. However, this effect was partly
recovered when cells were also incubated with 400μmol/L
NAC [68]. It is of notice that the concentration of NAC
employed in both studies was much lower than the concen-
tration employed in our study. Moreover, in the first study,
the cell culture medium containing NAC was discarded
before incubation with MGO. Besides, the concentration of
MGO used in the second study in INS-1 cells was much
higher than the amount we used. Nevertheless, MGO might
produce cytotoxic effects at different concentrations in
different cell lines, as shown by other authors [69–73]. The
recovery in cell viability upon coincubation with NAC might
be due to the capacity of NAC to scavenge free radicals, but it
may also be considered that it forms hemithioacetals with
MGO in the culture media (Figure 9).
We also saw that cells treated with these 1,2-dicarbonyls
produce different ROS, being MGO, which induces a greater
production of peroxides and superoxide anion in the cells.
Some previous studies have identified an increase in the
intracellular levels of ROS after treatment with AGEs [34–
36]. They found that glycated human serum albumin, rich
in AGEs, induced the expression of E-selectin in the endothe-
lial cells of HUVEC. However, when cells were preincubated
















Figure 9: Reaction of N-acetylcysteine with MGO under formation
of a hemithioacetal.
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oxidase, E-selectin expression was suppressed in a dose-
dependent manner. There was indeed an AGEs-induced pro-
duction of ROS, as it was shown by an increase in 2′,7-
dichlorofluorescein (DCF) fluorescence signal upon cell
treatment with AGEs [34]. Similar results have been reported
in a cellular model of macrophages. When these cells were
treated with the product of the reaction between MGO and
bovine serum albumin, rich in MGO-derived AGEs, ROS pro-
duction assayed by 2′,7′-dichlorofluorescein diacetate (DCFH-
DA) was increased. The origin of these ROS might be NADPH
oxidase since, upon incubation with AGEs, the mRNA of
NOX1 and NOX2 was highly increased. Moreover, ROS-
mediated damage to proteins, measured as protein carbonyls
and advanced oxidation protein products (AOPPs), was raised
as well upon incubation with AGEs. Interestingly, coincubation
with pterostilbene, a plant polyphenol with antioxidant
properties, decreased ROS production, NOX1 and NOX2
expression, and oxidative damage to proteins [36]. A recent
study performed in human endothelial cells showed that when
cells were incubated with glycated albumin, it was induced an
increase in the concentration of H2O2, O2
•-, and •NO as well
as an increase in CAT, GPX, and SOD1 activities and AOPPs
production. The source of these AGEs-induced ROS proved
to be the mitochondria and NADPH oxidases as tested
employing myxothiazol, an inhibitor of complex III of mito-
chondria, and the NADPH oxidase inhibitor, apocynin.
Furthermore, coincubation with a plant extract with a high
polyphenol content reduced the AGEs-mediated ROS produc-
tion in this cellular model [35]. Nevertheless, all of these studies
employed glycated albumin as a source of AGEs, and they did
not demonstrate the effect of individual compounds, while in
our study, we confirm that the molecules producing cytotoxic
effects in our cellular model are indeed 1,2-dicarbonyls.
In recent studies, it has been found that MGO also
induces ROS production in human embryonic kidney cells
[74]. In SH-SY5Y cells, it was reported an increase in H2O2,






























































































Figure 10: NLRP3 inflammasome and gasdermin activation upon incubation with 1,2-dicarbonyls. (a) NLRP3 inflammasome activation. A
representative western blot experiment is shown. Graphic represents the production of NLRP3 as analyzed by quantification of western-blot
optical density. (b) Gasdermin activation. A representative western blot experiment is shown. Graphic represents the production of
progasdermin and activated gasdermin as analyzed by quantification of western blot optical density. Arbitrary 1.0 value was given to the
CON group. Here, cell treatments consisted of 750μM 3-DGal, 75μM 3,4-DGE, 1mM Pyrr, and 1mM 3-DG. Results are expressed as
mean ± SEM (n = 3). ∗p < 0:05 vs. CON, ∗∗p < 0:01 vs. CON, ∗∗∗p < 0:001 vs. CON, ##p < 0:01 vs. progasdermin.
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O2
•-, and •NO production after incubating with MGO, which
also induced lipid peroxidation, protein carbonyls and thiols,
protein nitration, and DNA oxidative damage. Besides, all of
these effects were partly reversed by incubation with antiox-
idants [75]. However, all in vitro studies where the role of sin-
gle 1,2-dicarbonyls is investigated are performed employing
MGO, and here, we show for the first time an increased pro-
duction of ROS by 3-DGal, 3,4-DGE, and GO.
It is already studied that AGEs can produce cell death,
being the apoptosis proposed mechanism in the majority of
cases. However, in this work, we show that, when assayed
individually, not all of the compounds exert the same effect.
Indeed, we show that MGO induces apoptosis in our cellular
model, as assayed using Annexin-V staining and an inhibitor
of apoptosis. This is in agreement with some recently pub-
lished works where they show apoptotic death following
treatment with MGO [58, 76]. Nevertheless, when we
assayed 3-DGal and 3,4-DGE, we found that, surprisingly,
both 1,2-dicarbonyls do not enhance apoptosis in the cells.
Moreover, keratinocytes exposed to 3-DGal and 3,4-DGE
in the presence of inhibitors of death by autophagy, ferropto-
sis, and necroptosis were not able to preserve from death.
Interestingly, these compounds were able to induce the acti-
vation of gasdermin, the protein that triggers pyroptosis, one
form of programed necrosis. Thus, we propose here that ROS
produced by 3-DGal and 3,4-DGE promote pyroptosis through
NLRP-3 inflammasome activation [77, 78], leading to gasder-
min cleavage, following formation of pores in the membrane
of the cell and, thus, swelling and membrane rupture [79].
It has already been described that AGEs, by interaction
with their receptor RAGE, initiate several signal transduction
cascades such as NF-κB, which ultimately lead to the promo-
tion of inflammation or apoptosis, since they produce cyto-
kines, chemokines, and some proinflammatory molecules
[18, 23, 37, 80]. In this study, we show how 3-DGal and
3,4-DGE individually activate the NF-κB pathway for the
first time. The analysis shows a significant translocation of
the factor NF-κB at the nuclear level after 3,4-DGE and 3-
DGal treatment. The translocation of NF-κB causes an
increased expression of the NLRP3 inflammasome. NLRP3
inflammasome appears to be overexpressed and activated
after incubation with 3,4-DGE and 3-DGal. The activation
of the NLRP3 inflammasome is confirmed by the presence
of the N-terminal residue of GSDMD. After oligomerization,
the N-terminal residue of GSDMD inserts itself into the
membrane, generating the transmembrane pores responsible
for pyroptotic cell death. Pyroptosis may be the ROS-
dependent cell death mechanism implicated in reducing via-
bility in keratinocytes exposed to 3,4-DGE and 3-DGal.
3,4-DGE is a dehydration product of 3-DG and 3-DGal,
and it is the most cytotoxic compound examined in this
study. 3,4-DGE contains a, β,γ-unsaturated α-dicarbonyl
structure, which can undergo the Michael reaction in addi-
tion to the direct reaction of the carbonyl groups. Michael
reaction of 3,4-DGE with glutathione (GSH) leads to an irre-
versible adduct due to the depletion of GSH itself with a con-
sequent increase in oxidative stress [81], which causes the
activation of the detected signal pathways. It is interesting
to note that the signaling pathway activated by 3-DGal also
appear to be the same activated by 3,4-DGE, although to have
this comparable effect 3-DGal must be administered at a con-
centration 10 times higher than 3,4-DGE. Therefore, it is
proposed that 3-DGal cytotoxicity is due to facile dehydra-
tion of the compound to 3,4-DGE, which may be the actual
cytotoxic form. Furthermore, it should be noted that 3-DGal,
but not its epimer 3-DG, can give such effects. The reason
that 3-DG and 3-DGal exhibit two different cytotoxic behav-
iors may reside in the kinetics of dehydration to give 3,4-
DGE. In a literature report, the formation of 3,4-DGE from
3-DGal was observed to be faster than from 3-DG [82].
Finally, it is worth mentioning that the bioavailability of
these compounds might vary, given their chemical differ-
ences. Membrane solubility, the presence of compound
transporters, or perhaps the identification of receptor-
mediated signaling pathways in the toxicological profile of
AGEs and 1,2-dicarbonyls should be further investigated.
5. Conclusion
Isolated glycated amino acids and 1,2-dicarbonyls do not
deliver the same biological effect in human epithelial cells.
ROS production and cell death are mechanisms of cytotoxic-
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MAPK: Mitogen-activated protein kinases
MG-H1: Methylglyoxal-derived hydroimidazolone-1
MGO: Methylglyoxal




NADPH: Nicotinamide adenine dinucleotide phosphate
NF-κB: Nuclear factor kappa-light-chain-enhancer of
activated B cells
NLRP3: NOD-, LRR-, and pyrin domain-containing
protein 3
NOX1: NADPH oxidase 1
NOX2: NADPH oxidase 1








RAGE: Receptor for AGEs
RNase: Ribonuclease
ROS: Reactive oxygen species
SOD1: Superoxide dismutase 1
SOD2: Superoxide dismutase 2
TBS-T: Tris-buffered saline with 0.1% Tween ® 20
Detergent.
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